India's Wockhardt in fifth European acquisition
The Indian pharmaceutical company spends $265 million to acquire Negma Laboratories, a French research-based major with 172 patents.
Indian pharmaceutical and biotechnology company, Wockhardt, is to buy Negma Laboratories of France in an all-cash deal for $265 million that marks its fifth acquisition in Europe.
Negma is the fourth-largest independent integrated pharmaceutical group in France. For the most recent fiscal year it had sales of $150 million. Negma is a research-based company with 172 patents and leading positions in the osteoarthritisrheumatology, phlebotonic and the arterial hypertension segments. Wockhardt intends to use the patents to extend its business...
To continue reading, please login or register for free